v3.26.3
Stockholders’ Equity (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 23, 2026
Mar. 19, 2026
Feb. 04, 2026
Nov. 24, 2025
Oct. 16, 2025
Mar. 21, 2025
Feb. 25, 2025
Feb. 06, 2025
Oct. 01, 2024
Jan. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Jun. 23, 2025
Feb. 26, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Non controlling interest                     $ 8,440,000   $ 8,440,000     $ 9,547,000    
Shares issued for payment of legal fees                                 7,924 2,887
Legal fees received                                   $ 29,000
Reverse stock split 1-for-12.62                                  
Common stock, par value $ 0.001                   $ 0.02   $ 0.02     $ 0.02    
Common stock, shares issued                     10,042,518   10,042,518     9,092,518    
Common stock, shares outstanding                     10,042,518   10,042,518     9,092,518    
Number of grants shares issued                 69,731 253,577                
Purchase price per share                 $ 37.86                  
Proceeds from grants                 $ 2,640,000                  
Fair value grants                 $ 50,000                  
Stock based compensation expense                     $ 1,440,000   $ 1,440,000          
Non controlling interest                     $ 158,000   $ 158,000          
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Stock based compensation expense                       $ 2,000   $ 4,000        
Minimum [Member]                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Reverse stock split       1-for-12.48                            
Common stock, shares issued 8,600,000                                  
Common stock, shares outstanding 8,600,000                                  
Maximum [Member]                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Reverse stock split       1-for-50                            
Common stock, shares issued 107,800,000                                  
Common stock, shares outstanding 107,800,000                                  
Common Stock [Member]                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Stock Issued During Period, Value, Acquisitions             $ 1,150,000                      
Stock Issued During Period, Shares, Acquisitions             43,189                      
Stock issued for debt conversion         2,531,000                          
Impact Bio Medical Inc [Member]                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Number of shares sold           499,800                        
Value of shares sold           $ 1,500,000                        
Non controlling interest                             $ 205,000      
Aegis Capital Corp. [Member]                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Number of shares sold   50,000 900,000                              
Number of shares sold, per shares     $ 1.00                              
Net of expenses   $ 46,000 $ 657,000                              
Equity Incentive Plan [Member]                                    
Accumulated Other Comprehensive Income (Loss) [Line Items]                                    
Common stock under the plan for services               1,000,000                    
Common stock under the plan for services, value               $ 870,000